ENTX compared with ELTX: revenue, margins and what each company keeps, and the suppliers and customers both name

ENTXEntera Bio Ltd.

Mkt capRevenueRevenue

ELTXElicio Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ENTXEntera Bio Ltd.

ELTXElicio Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ENTX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±34.0%▲+5.92%×0.17

ELTX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±18.7%▼−1.90%×0.10

= impliedENTX realized, solidELTX realized, hatchedOne scale, both sides: full bar = 34%× = |realized| ÷ impliedSource: market data

ENTXEntera Bio Ltd.

3.21▲+2.88%· post 3.21

Mkt cap$161.4MRevenue$42,000Q1 FY25

ELTXElicio Therapeutics, Inc.

1.69▼−3.18%· post 1.69

ClosedOct 30 '26

Mkt cap$44.2MRevenue—

Compare

ClosedOct 30 '26

ENTXEntera Bio Ltd.

ELTXElicio Therapeutics, Inc.

3.21▲+2.88%post 3.21

Price

1.69▼−3.18%post 1.69

$161.4M

Mkt cap

$44.2M

Q1 FY25$42,000

Revenue

—

ENTX3.21▲+2.88%vsELTX1.69▼−3.18%ClosedOct 30 '26